Foghorn Therapeutics Inc.
USPTO PatentsView assignee record - 14 granted patents across 5 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Foghorn ranks #19,780 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 5 technology areas.
- #19,780
- of 49,997 US assignees by volume
- Top 15%
- by Innovation Score (49.2/100)
- 19.9
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R19780 · US Corporation #19,780 · 14 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 14 grants
- MID-PACK #19,780/49,997
- PHOTO-FINISH Firstface
- CPC-NARROW A61P · 5 areas
- INNOV-PAR 49.2/100
- CLAIMS-RICH 19.9 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2022–2025 · 4y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Firstface Co., Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Foghorn’s 49.2 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Foghorn
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Foghorn Therapeutics · this assignee
Foghorn Therapeutics · this assignee
49 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Foghorn's Innovation Score is 49.2/100 (top 15% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Foghorn?
Each dot is one of Foghorn’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Foghorn’s own 19.9 claims/patent is ABOVE the 14.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Foghorn's grants concentrate
Foghorn Therapeutics Inc. is a focused PatentsView assignee: 5 CPC subclasses with 92.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (5 grants) versus a trough of 1 in 2024. By volume, Foghorn sits between Firstface Co., Ltd. and FUNDAÃO Butantan.
Foghorn's three-year grant acceleration
Foghorn Therapeutics Inc. shows 9 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Foghorn's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Firstface
Firstface Co., Ltd.
14 patents
- Fives DMS
Fives DMS
14 patents
- Flanders Electric…
Flanders Electric Motor Service, LLC
14 patents
- Flexlink AB
Flexlink AB
14 patents
- Forever Gifts
Forever Gifts, Inc.
14 patents
- Fronteo
Fronteo, Inc.
14 patents
- FundaciÓ Institut…
FUNDACIÓ Institut D'INVESTIGACIÓ BIOMÈDICA DE Bellvitge (IDIBELL)
14 patents
- FundaÃO Butantan
FUNDAÃO Butantan
14 patents
- Foghorn Therapeut… ◀
Foghorn Therapeutics Inc.
14 patents
What this shows Foghorn holds 14 patents at rank #19,766, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Foghorn
By rank, the assignees closest to #19,766 in granted patent volume.
- Firstface Co., Ltd. #19,762 · 14 patents
- Fives DMS #19,763 · 14 patents
- Flanders Electric Motor Service, LLC #19,764 · 14 patents
- Flexlink AB #19,765 · 14 patents
- Forever Gifts, Inc. #19,767 · 14 patents
- Fronteo, Inc. #19,768 · 14 patents
- FUNDACIÓ Institut D'INVESTIGACIÓ BIOMÈDICA DE Bellvitge (IDIBELL) #19,769 · 14 patents
- FUNDAÃO Butantan #19,770 · 14 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Foghorn's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Foghorn's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
49 Top 15% higher than 85% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 3 | 21.4% |
| 2023 | 5 | 35.7% |
| 2024 | 1 | 7.1% |
| 2025partial year | 5 | 35.7% |
Which technologies does Foghorn Therapeutics Inc. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Foghorn Therapeutics Inc.'s patent record in context - here's where to go next.
- Foghorn Therapeutics Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.9% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #19,780 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Foghorn Therapeutics Inc. against Firstface Co., Ltd., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 49.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.